This article evaluates the economic impact of intravenous iron (in the form of intravenous iron preparation of ferric carboxymaltose) in three different clinical settings of iron deficiency anemia: chemotherapy-induced anemia in breast cancer, chemotherapy-induced anemia in digestive cancer, and perioperative anemia in knee and hip surgery. Lien vers l'article
LUPORSI, E., MAHI, L., MORRE, C., WERNLI, J., PUYOU DE POUVOURVILLE, G. and BUGAT, R. (2012). Evaluation of Cost Savings with Ferric Carboxymaltose in Anemia Treatment Through Its Impact on Erythropoiesis-Stimulating Agents and Blood Transfusion: French Healthcare Payer Perspective. Journal of Medical Economics, 15(2), pp. 225-232.